NAM
DXCM icon

Nissay Asset Management’s DexCom DXCM Stock Holding History

Nissay Asset Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.8M Buy
108,300
+2,208
+2% +$154K 0.04% 271
2025
Q4 		$7.04M Buy
106,092
+4,985
+5% +$322K 0.04% 267
2025
Q3 		$6.8M Buy
101,107
+1,747
+2% +$138K 0.04% 270
2025
Q2 		$8.67M Buy
99,360
+3,285
+3% +$257K 0.05% 234
2025
Q1 		$6.56M Buy
96,075
+7,497
+8% +$612K 0.04% 270
2024
Q4 		$7.11M Sell
88,578
-12,956
-13% -$959K 0.04% 261
2024
Q3 		$6.81M Buy
101,534
+8,656
+9% +$711K 0.04% 262
2024
Q2 		$10.5M Buy
92,878
+8,953
+11% +$1.13M 0.07% 182
2024
Q1 		$11.6M Buy
83,925
+16,289
+24% +$2.05M 0.08% 168
2023
Q4 		$8.39M Buy
67,636
+4,747
+8% +$485K 0.07% 175
2023
Q3 		$5.87M Buy
62,889
+3,527
+6% +$398K 0.05% 212
2023
Q2 		$7.63M Buy
59,362
+476
+0.8% +$57.6K 0.07% 177
2023
Q1 		$6.84M Sell
58,886
-12,778
-18% -$1.43M 0.06% 181
2022
Q4 		$8.12M Buy
71,664
+6,395
+10% +$702K 0.08% 159
2022
Q3 		$5.26M Buy
65,269
+2,089
+3% +$177K 0.06% 208
2022
Q2 		$4.71M Buy
63,180
+5,996
+10% +$547K 0.05% 224
2022
Q1 		$7.31M Buy
57,184
+1,028
+2% +$112K 0.06% 185
2021
Q4 		$7.54M Buy
56,156
+4,396
+8% +$632K 0.06% 195
2021
Q3 		$7.08M Buy
51,760
+1,732
+3% +$218K 0.06% 185
2021
Q2 		$5.34M Buy
50,028
+10,016
+25% +$962K 0.05% 226
2021
Q1 		$3.6M Sell
40,012
-828
-2% -$77.7K 0.04% 291
2020
Q4 		$3.77M Buy
40,840
+396
+1% +$35.4K 0.06% 259
2020
Q3 		$4.17M Sell
40,444
-7,408
-15% -$774K 0.07% 201
2020
Q2 		$4.85M Buy
47,852
+3,476
+8% +$311K 0.09% 203
2020
Q1 		$2.99M Buy
44,376
+2,412
+6% +$150K 0.08% 245
2019
Q4 		$2.29M Buy
41,964
+12,224
+41% +$580K 0.05% 365
2019
Q3 		$1.11M Buy
29,740
+1,752
+6% +$68.1K 0.03% 466
2019
Q2 		$1.05M Sell
27,988
-3,204
-10% -$101K 0.03% 485
2019
Q1 		$929K Buy
31,192
+1,684
+6% +$59.2K 0.02% 509
2018
Q4 		$884K Buy
+29,508
New +$936K 0.03% 477

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nissay Asset Management's DXCM Position: Q1 2026 in Review

Nissay Asset Management increased its DexCom (DXCM) stake by 2.1% in Q1 2026, buying an estimated $154K and bringing the position to 108,300 shares worth $6.8M. The position accounts for 0.04% of the portfolio, ranked #271.

Nissay Asset Management first reported a position in DXCM in Q4 2018 and has held it in 30 quarters since. The position peaked at $11.6M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Nissay Asset Management held 108,300 shares of DexCom worth $6.8M as of Q1 2026.
  • Nissay Asset Management bought 2,208 DexCom shares in Q1 2026, an estimated $154K.
  • DexCom made up 0.04% of Nissay Asset Management's portfolio in Q1 2026, its #271 holding.
  • Nissay Asset Management first reported a position in DexCom in Q4 2018 and has held it in 30 quarters since.
  • Nissay Asset Management's DexCom position peaked at $11.6M in Q1 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Nissay Asset Management's 13F filing for Q1 2026, filed 15 May 2026.